“…Evidence of hemolysis characterized by drop in hemoglobin, hematocrit and increase in reticulocyte count (3.6%) was observed on day four of admission for which PRBC transfusion was given. Next two days, we have Dapsone, a sulfone is a structural analog of paraaminobenzoic acid (PABA) and a competitive inhibitor of dihydropteroate synthase in the folate pathway [7]. The indications for dapsone are varied and include the management of Pneumocystis carinii pneumonia (PCP) in immunosuppressed patients, dermatitis vulgaris, herpetiformis, psoriasis, pemphigus, acne lupus erythematosus profundus, brown recluse spider bites, pyoderma gangrenous [7] prophylaxis and treatment of falciparum malaria maduromycosis, panniculitis due to alpha-1 antitrypsin deficiency [1,4,9].…”